Skip to main content
Premium Trial:

Request an Annual Quote

Genomatix Gets $500K in Series B Private Equity Round

NEW YORK, May 18 (GenomeWeb News) - Genomatix, a Roanoke, Va.-based gene expression and proteomics tools company, today announced that it has closed a Series B round of financing led by a $500,000 investment from NewVa Capital Partners, a venture capital fund managed by Third Security.


Robert Beech, CEO of Genomatix, said in a statement that the new funding will "accelerate the roll out and marketing of its proprietary genetic tools," and called NewVa's investment a "strong indicator" that the company was on the "right track, both scientifically and commercially."

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.